Skip to main content

Table 1 Clinical demographics of COPD patient subgroups

From: Defective monocyte-derived macrophage phagocytosis is associated with exacerbation frequency in COPD

  Stable patients
n = 92
Repeatability analysis
n = 36
Paired exacerbation patients
n = 39
Age (years) 71.9 (8.7) 69.3 (8.7) 71.5 (8.0)
FEV1 (L) 1.34 (0.52) 1.47 (0.58) 1.27 (0.55)
FEV1 (% predicted) 54.6 (17.6) 58.1 (18.4) 52.7 (18.8)
FVC (L) 2.86 (0.87) 2.90 (0.77) 2.69 (0.93)
FEV1/FVC (%) 47.6 (13.4) 50.7 (13.1) 48.2 (15.4)
Exacerbation frequency 2.0 [1.0–3.0] 2.0 [1.0–3.0] 2.5 [1.5–3.5]
Smoking pack years 50.0
[28.4–71.5]
45.3
[21.1–62.3]
45.6
[24.5–76.5]
ICS dose
(beclomethasone equivalent μg)
1000
[1000–2000]
1500
[1000–2000]
2000
[1000–2000]
N (%) Male sex 60 (65) 24 (67) 23 (59)
N (%) Current smokers 32 (35) 17 (47) 11 (28)
N (%) Chronic bronchitis 72 (78) 31 (86) 35 (90)
  1. Table shows data for stable COPD patients (n = 92), including subsets of patients used for repeatability experiments (n = 36) and patients with a paired stable and exacerbation sample (n = 39). Parametric data displayed as mean (SD), non-parametric data displayed as median (IQR) and categorical data displayed as N (%)